HepVu would like to highlight the recent Congressional Budget Office (CBO) report in which CBO describes its initial analysis of the potential federal budgetary effects of policies that would increase treatment of Hepatitis C, focusing on two sample national policies that would increase treatment rates among Medicaid enrollees.
In addition, we would like to draw your attention to the accompanying blog by Phillip L. Swagel, CBO’s Director, asking for comments on the report and inviting the submission of additional data to inform the analysis of the costs and benefits of expanded access to Hepatitis C treatment in the U.S.
